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InterventionsThe placebo effect in treating angina is powerful. Trials of internal mammary artery (IMA)
ligation in the 1950s using sham control arms revealed dramatic placebo effects with regard to
anginal symptoms. However, sham controls are rarely used in interventional trials for stable
coronary disease today. The FAME 2 (Fractional Flow Reserve Versus Angiography for Multi-
vessel Evaluation 2) trial, stopped early by its data safety and monitoring committee because of
increased urgent hospitalization and revascularization in the medical therapy arm, illustrates the
hazards of not including a sham control. A sham arm would have been ethically advantageous; it
would have posed little to no additional risk and would have substantially increased the social and
clinical value of the results. The lessons from this trial should prompt greater consideration and use
of sham controls in trials for stable coronary disease.IntroductionNeal W. Dickert,
MD, PhD*yz
Franklin G. Miller,
PhDxThe negative impact of stable ischemic disease on quality of life is clear, and some patients have
experienced remarkably reduced anginal burden after invasive interventions. In 1 case, a woman
with previously intractable angina was able to climb “28 steps to her second ﬂoor apartment” (1). In
another, a man “reported a 100 per cent improvement at 6 months and 75 per cent improvement
after a year” (2). Both patients were enrolled in studies of IMA ligation in the 1950s, but the
second patient had undergone a sham procedure. These famous and revolutionary sham-controlled
studies more than 50 years ago demonstrated both the lack of efﬁcacy of IMA ligation and the
power of placebo in treating angina (3).
These powerful lessons unfortunately have not been widely applied. Few sham-controlled
studies of invasive interventions to treat stable coronary disease have been performed since then,
with notable exceptions including studies of transmyocardial laser revascularization, another
procedure that proved ineffective (4). Although medications to treat coronary disease are routinely
tested in double-blind, placebo-controlled trials, treatment assignment in most randomized
interventional trials has been unblinded. This has important implications for clinical knowledge
and practice. Physicians and patients must make decisions on the basis of incomplete information,
patients may be exposed to risks not justiﬁed by clinical beneﬁt, and the widespread use of
ineffective or marginally effective therapies means that health care resources may be consumed
inefﬁciently. Awareness of the role of sham-controlled trials in addressing these concerns has
increased in the wake of recent revelations regarding the SYMPLICITY HTN-3 trial of renal
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343FAME 2The FAME 2 trial highlights the need for sham
controls in the context of interventions for stable
coronary disease (6). Designed to evaluate the role
of fractional ﬂow reserve (FFR) assessment in revas-
cularization decisions for patients with stable angina
or documented ischemia and 50% stenosis in at least
1 major epicardial vessel, this trial randomized patients
with ﬂow-limiting stenosis (FFR < 0.8) to percuta-
neous coronary intervention (PCI) plus optimal
medical therapy (OMT) or OMT alone. FAME
2 clearly addressed a critical question in the post–
Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation era (7). It was well
positioned to produce results with great social value.
FAME 2 was stopped early by its data safety and
monitoring board, principally because of a signiﬁcant
increase in urgent revascularization, 1 of the compo-
nents of the composite primary endpoint. Only 1.6% of
PCI-treated patients underwent urgent revasculariza-
tion, compared with 11.1% in the OMT arm (hazard
ratio: 0.13; p < 0.001). Importantly, most urgent
revascularization was driven by presentation of unstable
angina not marked by objective elevations in cardiac
enzymes or electrocardiographic changes. Despite
rigorous adjudication procedures, this is an inevitably
“soft” endpoint, and critics expressed frustration that
the trial’s design failed to ensure clariﬁcation of the
effect of an FFR-guided strategy on mortality or
recurrent myocardial infarction (8). However, as de-
fenders of the trial have also pointed out, reducing
unstable angina is an important goal. What has received
less attention is the vulnerability of this endpoint to
placebo (or nocebo) effects and the easy avoidance of
this problem through the use of a sham control.
By FFR, all FAME 2 participants had hemody-
namically signiﬁcant stenosis that would convention-
ally be treated with PCI. The experimental group was
in essence the OMT group. These patients and their
physicians were thus aware that they had “untreated”
stenoses, knowledge that could profoundly affect their
likelihood of hospital presentation and diagnosis with
unstable angina. First, angina is a placebo-responsive
condition, as illustrated by the IMA trials. Second,
independent of the placebo effect, angina often per-
sists in both medically treated and revascularized pa-
tients. However, the experience of angina for patients
who know that they have been “ﬁxed” is likely very
different compared with the experience of those who
are “untreated.” This difference may drive both greater
anxiety and more likely presentation to a hospital
when angina occurs. Finally, a physician encountering
a patient with angina in the context of a knownhemodynamically signiﬁcant stenosis is surely more
inclined to diagnose unstable angina, perform cathe-
terization, and intervene than if the lesion is known to
have been “ﬁxed” (8). In summary, because of the lack
of blinding, there is every reason to believe that an
appreciable expectation-induced nocebo effect, oper-
ating on both patients and physicians, was operative in
this trial and may have contributed to worse outcomes
in the OMT group.The SolutionThese challenges could have been substantially miti-
gated by blinded treatment assignment using a sham
control. Because patients were randomized in the
catheterization laboratory after FFR was assessed,
the sham could have been as simple as a few extra
minutes on the table and the use of earphones or
other modalities to prevent the patient from over-
hearing conversations about treatment. Perhaps the
most complicated issue would have been the post-
procedural use of dual-antiplatelet therapy (DAPT).
The simplest solution would be to treat all patients
with DAPT, although it would involve some excess
risk for bleeding and could affect ischemic outcomes.
A more conservative approach more reﬂective of
current management would be to give placebo DAPT
to the OMT group. Either choice would have been
defensible and would substantially address concerns
about placebo and nocebo effects in this trial.
The beneﬁts of a sham design from a societal
perspective are clear. Given the high volume of PCI
performed yearly for stable coronary disease, we have a
substantial collective interest in targeting therapy and
reducing unnecessary intervention, a goal of the FFR
strategy itself. Moreover, cost-effectiveness assess-
ments of PCI and FFR, which are particularly
important in the absence of a clear reduction in
myocardial infarction or mortality, are directly affected
by these design issues. Independent of cost, patients
have a strong interest in avoiding potential compli-
cations of PCI and the risks of DAPT. Perhaps most
important, data from a sham-controlled study would
offer the most complete information possible to help
physicians and patients arrive at shared decisions
regarding the best approach to management, an
important goal given that the principal beneﬁt of
PCI for stable disease is symptom reduction.Ethical Implications of
Sham ControlsSham-controlled trials do raise ethical concerns, most
of which relate to the risks of the sham procedure
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344itself. However, a sham design in this trial would raise
few such concerns. First, the potential value of the
scientiﬁc information is a signiﬁcant ethical advantage.
Second, the sham procedure would involve little more
than simple machinations to make patients believe
they had undergone PCI after FFR. There would be
essentially no additional risks imposed during the
procedure. Some sham-associated risks may be
necessary and justiﬁable in some cases (as with IMA
ligation); however, sham controls are particularly
important when those risks are minimal. Third, some
may argue that depriving patients or clinicians of
treatment assignment on presentation to the hospital
would negatively affect management, but this argu-
ment seems unfounded. Appropriate unblinding
mechanisms could be put in place to manage bleeding
complications, for example, or need for surgical
treatment (so that antiplatelet medication discontin-
uation could be evaluated). These concerns require
planning but are not signiﬁcant barriers.
Sham controls and other methods of blinding play a
critical, and ethical, role in interventional trials in
which endpoints are subjective or are prone to being
inﬂuenced by expectations on the part of physicians or
patients. The inclusion of a sham arm in the SYM-
PLICITY HTN-3 trial distinguished it from multiple
prior and overwhelmingly positive studies that led to
the approval and clinical use of this therapy in many
countries (9). Although the full results have not yet
been presented, the failure of this trial to meet its
primary efﬁcacy endpoint has shocked the cardiology
community and illustrates the potentially pivotal role
sham controls can play (5). Blinded lead deactivation
has similarly been critical in rigorous trials of cardiac
resynchronization therapy (10,11).
There are strong ethical reasons to favor the broader
use of sham controls to study interventions for stable
coronary disease. They have provided critical knowl-
edge in the past and could be instrumental inanswering 1 of the most important and lingering
clinical questions in medicine: who beneﬁts from
interventions for stable coronary disease?Address correspondence to:
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